Literature DB >> 32241937

Tuning drug binding.

Dea Slade1, Sebastian Eustermann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32241937      PMCID： PMC7612557          DOI： 10.1126/science.abb1462

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  14 in total

Review 1.  Perspectives on PARPs in S Phase.

Authors:  Hana Hanzlikova; Keith W Caldecott
Journal:  Trends Genet       Date:  2019-04-26       Impact factor: 11.639

2.  Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Authors:  Junko Murai; Shar-Yin N Huang; Amèlie Renaud; Yiping Zhang; Jiuping Ji; Shunichi Takeda; Joel Morris; Beverly Teicher; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

3.  Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Authors:  Ann-Gerd Thorsell; Torun Ekblad; Tobias Karlberg; Mirjam Löw; Ana Filipa Pinto; Lionel Trésaugues; Martin Moche; Michael S Cohen; Herwig Schüler
Journal:  J Med Chem       Date:  2016-12-21       Impact factor: 7.446

4.  PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain.

Authors:  Jennine M Dawicki-McKenna; Marie-France Langelier; Jamie E DeNizio; Amanda A Riccio; Connie D Cao; Kelly R Karch; Michael McCauley; Jamin D Steffen; Ben E Black; John M Pascal
Journal:  Mol Cell       Date:  2015-11-25       Impact factor: 17.970

5.  Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Authors:  Todd A Hopkins; Yan Shi; Luis E Rodriguez; Larry R Solomon; Cherrie K Donawho; Enrico L DiGiammarino; Sanjay C Panchal; Julie L Wilsbacher; Wenqing Gao; Amanda M Olson; DeAnne F Stolarik; Donald J Osterling; Eric F Johnson; David Maag
Journal:  Mol Cancer Res       Date:  2015-07-27       Impact factor: 5.852

6.  Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.

Authors:  Marie-France Langelier; Jamie L Planck; Swati Roy; John M Pascal
Journal:  Science       Date:  2012-05-11       Impact factor: 47.728

Review 7.  PARP and PARG inhibitors in cancer treatment.

Authors:  Dea Slade
Journal:  Genes Dev       Date:  2020-02-06       Impact factor: 11.361

8.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312

9.  Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.

Authors:  Sebastian Eustermann; Wing-Fung Wu; Marie-France Langelier; Ji-Chun Yang; Laura E Easton; Amanda A Riccio; John M Pascal; David Neuhaus
Journal:  Mol Cell       Date:  2015-11-25       Impact factor: 17.970

10.  Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Authors:  Stephen J Pettitt; Dragomir B Krastev; Inger Brandsma; Amy Dréan; Feifei Song; Radoslav Aleksandrov; Maria I Harrell; Malini Menon; Rachel Brough; James Campbell; Jessica Frankum; Michael Ranes; Helen N Pemberton; Rumana Rafiq; Kerry Fenwick; Amanda Swain; Sebastian Guettler; Jung-Min Lee; Elizabeth M Swisher; Stoyno Stoynov; Kosuke Yusa; Alan Ashworth; Christopher J Lord
Journal:  Nat Commun       Date:  2018-05-10       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.